Taysha Gene (TSHA) Hovers Around Its 52-Week High As It Continues to Advance Rett Syndrome Program

Core Insights - Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is recognized as one of the 12 best multibagger stocks to buy heading into 2026 due to strong 1-year returns and upside potential [1] Group 1: Stock Performance and Market Sentiment - As of December 17, 2025, Taysha Gene is maintaining levels near its 52-week high, with peaks at $5.95 on December 12 and 13, indicating heightened investor sentiment as the company advances its Rett syndrome program [2] - Goldman Sachs upgraded Taysha Gene on December 4, 2025, from an Early-Stage Biotech designation to "Buy," setting an $11 price target based on optimism around TSHA-102 and a belief in achieving a 33% response rate in the REVEAL study [3] Group 2: Regulatory and Clinical Developments - In Q3 2025 results announced on November 4, 2025, Taysha Gene received FDA Breakthrough Therapy Designation for TSHA-102 for Rett syndrome and finalized alignment with the FDA on the REVEAL trial protocol, which includes a six-month interim analysis that could support a future Biologics License Application [4] - The company regained full rights to TSHA-102 in October, enhancing its strategic flexibility [4] Group 3: Company Focus and Strategy - Taysha Gene Therapies is focused on developing gene therapy treatments for severe genetic diseases of the central nervous system, with a primary emphasis on advancing TSHA-102 for Rett syndrome [5]